Numinus announces enrolling the first volunteer patient as it hosts a MAPS clinical trial for an MDMA-assisted treatment for PTSD.
Numinus announces enrolling the first volunteer patient as it hosts a MAPS clinical trial for an MDMA-assisted treatment for PTSD.
Enveric Biosciences announces that it has expanded on its psychedelic drug R&D pipeline along with filing a new patent application.
After strong preclinical testing results, Cybin is looking to advance CYB003 into a Plase 1/2a clinical trial, estimated for mid-2022.
MindMed reports its full-year results for 2021. Progress on major R&D initiatives. Cash balance of $133.5 million.
Novamind announces plans to expand group therapy within its clinical therapy model.
Mydecine reports conditional approval to commence a Phase IIb study on smoking cessation, in partnership with Johns Hopkins University.
Pharmather reports positive tolerability and dose-finding results in its clinical trial of a ketamine-based drug for Parkinson's disease as it prepares for a Phase III trial.
Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.
Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.
Awakn Life Sciences announces closing a a CAD $3.25 million private placement, with units priced at $1.60 along with a half-warrant with an exercise price of $2.20.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now